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inflammation, muscular pain, joint pain, rheumatic pain, neuralgia, soft tissue injuries and immobility Meloxicam is a potent anti-inflammatory agent, associated with lameness, arthritis and myositis [1,4, being a relatively selective Cox-2 inhibitor [1], in 5]. In veterinary practice Meloxicam was introduced comparison to older non-steroidal anti inflammatory for management of canine osteoarthritis and since then drugs (NSAIDs) which none selectively also inhibit it is being used for the management of pain and inflaCox-1 isoenzyme, leading to serious gastrointestinal mmation, arising from both acute and chronic conditions and renal side effects. Meloxicam is 12 times more [3, 7, 8] . In cattle it is used to treat pain, mastitis, selective in inhibiting Cox-2 activity than Cox-1 activity pneumonia and other inflammatory conditions [9, 10] . [2, 3] . The higher selectivity results in low ulcerogenic Indications for meloxicam use in farm animals include potential and less gastrointestinal irritation as compared respiratory infections and acute mastitis [11] . It is being to other NSAIDs [4, 5] . This less toxicity of the drug increasingly used in manage-ment of musculoskeletal makes it a broad spectrum drug covering a varying disorders for reduction in pain and inflammation [12] . number of diseases. In conjunction with a suitable Pharmacokinetic profile of meloxicam has been antibiotic, it is used as a drug of choice in many diseases elucidated in human beings [1,4], cattle [10, 11] , sheep [4, 5] . Meloxicam prevents ongoing occurrence of and goat [13, 14] , rabbit [15] , vulture [16] , horses [17], inflammation by inhibiting prostaglandin production, camels [18] , piglets [19] , green iguanas [20] , cats [21] , that sensitize the afferent nociceptors at peripheral sites llamas [22] and many other species of animals.. But of inflammation [6, 7] . data of one species cannot be extrapolated and used in In man it is used for treating non descriptive other species due to high interspecies variation in the pyrexia, painful conditions due to acute and chronic metabolism of meloxicam. The above collected the start of experimentation with the help of fenbenplasma was used for the analysis of the drug. 0.5 ml of dazole which was given at the rate 1ml/kg body weight.
plasma was mixed with 0.5 ml of acetonitrile. Vortex Mixer was used to mix the two and the mixture was Instruments used: High performance liquid chromathen centrifuged for 20 minutes at 6200 rpm. Clear tography (HPLC) system. Waters HPLC system supernatant was collected and 0.5 ml of HPLC grade consisting of a Degasser, two pumps A and B (Waters water was added to it. The aliquot thus obtained was 515 HPLC pump), an injector, C-18 symmetry column filtered through 0.22 µm nylon filter paper. 20 µl of this (particle size 5 µm; 4.6 mm x 250 mm), Waters 2487 filtrate was introduced into HPLC system. dual λ absorbance detector and a screen was used. of plasma and then plasma standards were prepared. collection tubes, 5ml).Tarpons 1.5 ml micro-centrifuge Quantification of drug was done from its respective tubes. 0.22 µm nylon filter. Test tubes, Flasks, measuring peak area and calibration curves were employed to cylinders, spirit, cotton, scissors. Syringes (2 ml and 5 determine the concentration of drug in plasma samples. ml).
Determination of meloxicam concentration in a repreDrugs and chemicals used: Pure standard Meloxicam sentative sample of goat is depicted in Figure- Results presented in Table-1 . Mean peak plasma level of drug was 1.972± 0.047 Amount of the drug present in the plasma samples µg/ml at 600 min, which decreased quickly to 1.314± of the goats at different time periods was used to 0.0271 µg/ml at 840 min of time. From this time onwards elucidate different pharmacokinetic determinants.
the decrease is uniform and the smallest concentration Magnitude of drug at varying times in the plasma of of about 0.3314±0.0271µg/ml was detected at 2880 goats after its single oral administration has been min. This decrease of drug with respect time in goat present study was 1472.264 ± 63.3305 min which is plasma has been depicted in Figure-2 . significantly lower than in cattle (2700 min) [9, 10] , This quantification of meloxicam in plasma samples again indicating that the drug is excreted quickly in of goat was used to arrive at different pharmacokinetic goats than in cattle. This is supported by the fact that determinants which have been presented in Table-2. meloxicam has a bit more tissue binding in cattle than The value of elimination half-life (t ) was 693 ± in goat [4] . 380892.4744 µg/min /ml respectively. The mean value bioavailibity (F) were found to be 497 ± 19.8041 min of volume of distribution (Vd) was 0.114 ± 0.156 L/kg and 80.5 ± 10.01498 % respectively. 0.7 µg/ml of which is less than cattle (0.242 L/kg) [10] . This plasma is the minimum effective therapeutic concenindicates that the meloxicam is well distributed in tration of drug and it was present up to 1200 min after a cattle than in goats when given orally. single oral administration. The mean values of AUC and AUMC were 3137.488±125.3749 µg/min/ml and [15] body weight/10 hours is advised to maintain its and Vultures [16] . The mean peak plasma level of effective concentration. The elimination of the drug meloxicam was 1.972 ± 0.0476 at 600 min, which was slow and the mean value of volume of distribution declined rapidly to 1.314 ± 0.0271 µg/ml at 840 min of (Vd) was lesser after oral administration which time, thereafter the decline was steady and the lowest indicates that the overall absorption and distribution of concentration of 0.334 ± 0.0282 µg/ml was observed at the drug after oral administration was very slow when 2880 min.
compared to intravenous route of administration. Mean The time to achieve maximum plasma residence time is more than double after oral concentration (T ) was found to be 497 ± 19.8040 max administration than after IV administration min which was less than that observed in calves [9, 10] Authors' contributions but was more than dogs (450 min) [26, 27] and rabbits (360 min) [15] . This implies that the peak drug Implementation of study design, experimentation and concentration is achieved rapidly in the plasma of goats data recording was done by ARW and RKR. SUN, in comparison to cattle.
OSS, SAB and NAK carried out analysis. ARW drafted The value of bioavailibity (F) was found to be and revised the manuscript. All the authors read and 80.5 ± 10.0150 % in the present study. This is less than approved the final manuscript. that found in cattle (100%) and horses (98 %) [10, 17] .
